Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Tocris Bioscience™ ARCC 4

Click to view available options
Quantity:
5 mg
Description
ARCC 4 is a potent and selective androgen receptor (AR) PROTAC™ Degrader (DC50 = 5 nM). Comprises an androgen receptor antagonist, enzalutamide, joined by a linker to a VHL E3 ligase ligand. Brings about degradation of ARs in VCaP and LNCaP prostate cancer cell lines (Dmax = 98% at 12h) in a proteasome-dependent manner, and inhibits cell proliferation. Also degrades clinically relevant AR mutants expressed in HEK293T cells. Exhibits no significant effect on glucocorticoid, estrogen or progesterone receptors at concentrations inducing AR degradation.
ARCC 4 negative control (Cat. No. 7255) also available.
PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.
Specifications
Specifications
Chemical Name or Material | (2 S,4 R)-1-(-2-(2-(4-((4 '-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-[1,1 '-biphenyl]-4-yl)oxy)butoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxami |
CAS | 1973403-00-7 |
Quantity | 5 mg |
Target | Active Degraders |
Molecular Formula | C53H56F3N7O7S2 |
Purity | 0.98 |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction